» Articles » PMID: 25714665

Involvement of MiR-133a and MiR-326 in ADM Resistance of HepG2 Through Modulating Expression of ABCC1

Overview
Journal J Drug Target
Publisher Informa Healthcare
Date 2015 Feb 26
PMID 25714665
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have shown that a class of small, functional RNAs, named microRNAs, may regulate multidrug resistance-associated protein 1 (ABCC1). Since ABCC1 is an important efflux transporter responsible for cellular drug disposition, the discovery of microRNAs (miRNA) brings an idea that there may be some other unknown multidrug resistance (MDR) mechanisms exist. Using computational programs, we predicted that the 3'untranslated region (3'UTR) of ABCC1 contains a potential miRNA binding site for miR-133a and also two other for miR-326. These binding sites were confirmed by luciferase reporter assay. ABCC1 mRNA degradation was accelerated dramatically in cells transfected with miR-133a or miR-326 mimics using qRT-PCR, Furthermore, western blot analysis indicated that ABCC1 protein expression was significantly down-regulated in hepatocellular carcinoma cells line HepG2 after transfection with miR-133a or miR-326 mimics, suggesting the involvement of mRNA degradation and protein expression mechanism. The effects of the two miRNAs on adriamycin (ADM) sensitivity to HepG2 cells were determined by MTT assay. Compared with mock transfection, miR-133a or miR-326 mimics transfection sensitized these cells to ADM. These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells.

Citing Articles

MiRNAs: main players of cancer drug resistance target ABC transporters.

Mohammadi F, Nejatollahi M, Sheikhnia F, Ebrahimi Y, Mohammadi M, Rashidi V Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39808313 DOI: 10.1007/s00210-024-03719-y.


MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.

Lu X, Jin H Front Pharmacol. 2024; 15:1486783.

PMID: 39679367 PMC: 11638538. DOI: 10.3389/fphar.2024.1486783.


Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs.

Wang Y, Tu M, Yu A Front Pharmacol. 2024; 15:1423416.

PMID: 39114355 PMC: 11303158. DOI: 10.3389/fphar.2024.1423416.


The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance.

Tavakoli Pirzaman A, Alishah A, Babajani B, Ebrahimi P, Sheikhi S, Moosaei F Technol Cancer Res Treat. 2024; 23:15330338241239188.

PMID: 38634139 PMC: 11025440. DOI: 10.1177/15330338241239188.


The role and impact of alternative polyadenylation and miRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1/ABCC1) in epithelial ovarian cancer.

Marjamaa A, Gibbs B, Kotrba C, Masamha C Sci Rep. 2023; 13(1):17476.

PMID: 37838788 PMC: 10576765. DOI: 10.1038/s41598-023-44548-y.